ArticleLangenbeck's archives of surgery2026
A Validated, explainable machine learning-based preoperative risk model for microvascular invasion in hepatocellular carcinoma.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis investigation aimed to develop and validate a diagnostic algorithm for preoperatively assessing the likelihood of microvascular invasion (MVI) in patients with hepatocellular carcinoma (HCC).
methodsClinical and pathological information of patients with HCC who underwent curative resection was collected from two medical centers. Data from Nanjing Drum Tower Hospital were randomly split into training (80%) and internal validation (20%) cohorts, while data from Northern Jiangsu People's Hospital were employed as an independent external validation cohort. Feature engineering was performed using recursive feature elimination (RFE) within the training cohort. Various machine learning models were applied, and their performance was evaluated through diverse metrics, such as receiver operating characteristic (ROC) curves. Additionally, the Shapley Additive Explanations (SHAP) method, together with tumor differentiation, Ki-67, and other relevant markers, were employed to enhance model interpretability and reliability.
resultsAmong the 1106 patients enrolled, 315 were pathologically confirmed to have MVI. RFE identified tumor diameter, alpha-fetoprotein (AFP), gamma-glutamyl transferase (GGT), and pan-immune-inflammation value (PIV) as key determinants of MVI risk in patients with HCC. With these variables, the XGBoost model reached area under the curve (AUC) values of 0.893 in the training cohort, 0.845 in the internal validation cohort, and 0.793 in the external validation cohort. Correlation analyses revealed that the risk score showed significant associations with tumor differentiation and the expression of Ki-67 proliferation index, Glypican-3 (GPC3), Cytokeratin 19 (CK19), and Vascular endothelial growth factor receptor 2 (VEGFR2).
conclusionAn XGBoost model incorporating tumor diameter, AFP, GGT, and PIV exhibited robust performance in assessing preoperative MVI among HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.